Anat Cohen-dayag on capital raising
From A Biopharma Pivot Story With Compugen's Dr. Anat Cohen-Dayag · · Life Science Connect
“From the capital perspective we were a public company so we went public already in 2000 and it's a different company obviously and so we could leverage the fact that we are a public company and we use different financial instruments to bring money in order to initiate the pipeline first and then when we had enough proof or early stage data we could start thinking about public offerings.”
On , Anat Cohen-dayag, Executive Chair at Compugen, spoke about capital raising during A Biopharma Pivot Story With Compugen's Dr. Anat Cohen-Dayag on Life Science Connect.
About Anat Cohen-dayag
Dr. Anat Cohen-Dayag, Executive Chair at Compugen, discussed the company's transformation from a computational biology service provider into a clinical-stage biopharmaceutical company focused on cancer immunotherapy. In a 2021 interview, she described how the company leveraged its status as a public company, using different financial instruments to fund its pipeline before having sufficient early-stage data to pursue public offerings. She noted that Compugen entered into a collaboration with Bayer, licensing to them the rights to develop drugs for one of the targets the company identified. Cohen-Dayag also outlined Compugen's strategy, which includes advancing its clinical-stage pipeline, developing early-stage programs to feed that pipeline, and using its computational engine to sustain its own discoveries. She stated that after presenting clinical data and establishing collaborations with Bristol-Myers Squibb, AstraZeneca, and Bayer, the company conducted another round of offering.